Table 4 Summary of adverse events for the treatment with short-acting exenatide
Adverse events | Number of patients (n = 754) | Number of events |
|---|---|---|
Any adverse events | 173 (22.94%) | 246 |
Serious adverse events | 6 (0.80%) | 6 |
Gastro-intestinal adverse events | 116 (15.38%) | 154 |
Nausea | 93 (12.33) | 100 |
Vomiting | 19 (2.52%) | 19 |
Dyspepsia | 8 (1.06%) | 8 |
Constipation | 7 (0.93%) | 7 |
Diarrhoea | 5 (0.66%) | 5 |
Others | 13 (1.72%) | 15 |
Metabolic and endocrine adverse events | 22 (2.92%) | 23 |
Hypoglycaemia | 13 (1.72%) | 14 |
Others | 9 (1.19%) | 9 |
Neuropsychologic adverse events | 25 (3.32%) | 29 |
Dizziness | 7 (0.93%) | 7 |
Headache | 6 (0.80%) | 6 |
Anorexia | 5 (0.66%) | 5 |
Others | 9 (1.19%) | 11 |
Cardiovascular adverse events | 5 (0.66%) | 5 |
Respiratory system adverse events | 3 (0.40%) | 3 |
Urinary system adverse events | 1 (0.13%) | 1 |
Musculo-skeletal or generalized adverse events | 16 (1.21%) | 18 |
Others | 11 (1.46%) | 13 |